Option Care Health (NASDAQ:OPCH) Earns "Outperform" Rating from Barrington Research

Option Care Health (NASDAQ:OPCH - Get Free Report)'s stock had its "outperform" rating reiterated by research analysts at Barrington Research in a research report issued to clients and investors on Wednesday, Benzinga reports. They currently have a $38.00 target price on the stock. Barrington Research's price objective would indicate a potential upside of 26.96% from the company's previous close.

Separately, Jefferies Financial Group upped their price objective on shares of Option Care Health from $36.00 to $38.00 and gave the stock a "buy" rating in a research report on Monday, March 4th.

Option Care Health Stock Down 2.2 %

Shares of OPCH traded down $0.66 on Wednesday, reaching $29.93. The company's stock had a trading volume of 2,852,184 shares, compared to its average volume of 1,279,544. The company has a current ratio of 1.77, a quick ratio of 1.33 and a debt-to-equity ratio of 0.74. Option Care Health has a twelve month low of $24.23 and a twelve month high of $35.74. The stock has a market capitalization of $5.20 billion, a PE ratio of 20.54, a PEG ratio of 1.73 and a beta of 1.22. The firm has a fifty day moving average of $32.19 and a 200-day moving average of $31.53.

Option Care Health (NASDAQ:OPCH - Get Free Report) last posted its earnings results on Tuesday, April 23rd. The company reported $0.26 earnings per share for the quarter, topping analysts' consensus estimates of $0.22 by $0.04. Option Care Health had a net margin of 6.21% and a return on equity of 18.78%. The company had revenue of $1.15 billion for the quarter, compared to analyst estimates of $1.10 billion. During the same quarter in the prior year, the business posted $0.21 EPS. The firm's revenue was up 12.8% compared to the same quarter last year. Equities analysts predict that Option Care Health will post 1.13 EPS for the current year.

Insiders Place Their Bets

In other news, Director Harry M. Jansen Kraemer, Jr. acquired 35,000 shares of Option Care Health stock in a transaction on Monday, February 26th. The stock was acquired at an average cost of $31.55 per share, with a total value of $1,104,250.00. Following the transaction, the director now owns 269,528 shares of the company's stock, valued at approximately $8,503,608.40. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. 0.64% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of OPCH. Vontobel Holding Ltd. grew its position in shares of Option Care Health by 2.9% during the 3rd quarter. Vontobel Holding Ltd. now owns 13,168 shares of the company's stock valued at $426,000 after acquiring an additional 374 shares during the period. IFP Advisors Inc grew its position in shares of Option Care Health by 20,350.0% during the 3rd quarter. IFP Advisors Inc now owns 2,454 shares of the company's stock valued at $79,000 after acquiring an additional 2,442 shares during the period. SG Americas Securities LLC grew its position in shares of Option Care Health by 1,638.4% during the 3rd quarter. SG Americas Securities LLC now owns 84,729 shares of the company's stock valued at $2,741,000 after acquiring an additional 79,855 shares during the period. State of Alaska Department of Revenue grew its position in shares of Option Care Health by 4.3% during the 3rd quarter. State of Alaska Department of Revenue now owns 21,376 shares of the company's stock valued at $691,000 after acquiring an additional 880 shares during the period. Finally, Avior Wealth Management LLC grew its position in shares of Option Care Health by 30.5% during the 3rd quarter. Avior Wealth Management LLC now owns 15,706 shares of the company's stock valued at $508,000 after acquiring an additional 3,670 shares during the period. 98.05% of the stock is owned by institutional investors.

Option Care Health Company Profile

Option Care Health, Inc offers home and alternate site infusion services in the United States. The company provides anti-infective therapies; home infusion services to treat heart failures; home parenteral nutrition and enteral nutrition support services for numerous acute and chronic conditions, such as stroke, cancer, and gastrointestinal diseases; immunoglobulin infusion therapies for the treatment of immune deficiencies; and treatments for chronic inflammatory disorders, including crohn's disease, plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, and other chronic inflammatory disorders.